Quercetin inhibits proliferation and increases sensitivity of ovarian cancer cells to cisplatin and paclitaxel

Ginekologia Polska

Volumn 84, Issue 7, 2013, Pages 590-595

  Maciejczyk, Adam ^a   Surowiak, Pawei ^b  

^a Wroclaw   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Chemoresistance; Cisplatin; Ovarian cancer; Paclitaxel; Quercetin

Indexed keywords

EID: 84881643723     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: 10.17772/gp/1609     Document Type: Article

References (18)

1. Cannistra S. Cancer of the ovary. N Engl J Med. 2004, 351, 2519-2529.
2. Nowak-Markwitz E, Maciejczyk A, Pudelko M, [et al.]. Influence of tamoxifen on cisplatin-sensitivity and estrogen receptors expression in ovarian carcinoma cell lines. Ginekol Pol. 2010, 81, 183-187.
3. Miedzinska-Maciejewska M, Wcislo G, Bodnar L. Modulation of multidrug resistance in ovarian cancer patients. [in Polish]. Wspólczesna Onkologia. 2004, 9, 457-465.
4. Manach C, Williamson G, Morand Ch, [et al.]. Bioavailability and bioefficacy of polyphenols in humans. Review of 97 bioavailability studies. Am J Clin Nutr. 2005, 81, 230-242.
5. Wu C, Ohnuma S, Ambudkar S. Discovering Natural Product Modulators to Overcome Multidrug Resistance in Cancer Chemotherapy. Curr Pharm Biotechnol. 2011, 12, 609-620.
6. Jakubowicz-Gil J, Paduch R, Piersiak T, [et al.]. The effect of quercetin on pro-apoptotic activity of cisplatin in HeLa cells. Biochem Pharmacol. 2005, 69, 1343-1350.
7. Györffy B, Surowiak P, Kiesslich O, [et al.]. Resistance prediction profile for eleven anticancer agents at clinical concentrations based on the gene expression pattern of thirty cell lines. Int J Cancer. 2006, 118, 1699-1712.
8. Surowiak P, Materna V, Kaplenko I, [et al.]. ABCC2 (MRP2, cMOAT) Can be localized in the nuclear membrane of ovarian carcinomas and correlates with resistance to cisplatin and clinical outcome. Clin Cancer Res. 2006, 12, 7149-7158.
9. Stanisz A. An accessible course of statistics using Statistica Pl software and examples from medicine. [in Polish]. Kraków: Statsoft, 2007.
10. Kowalski P, Surowiak P, Lage H. Reversal of different drug-resistance phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2 and BCRP. Mol Ther. 2005, 11, 508-522.
11. Hu W, Wu W, Verschraegen C, [et al.]. Proteomic identification of Heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics. 2003, 3, 1904-1911.
12. Jakubowicz-Gil J, Paduch R, Gawron A, Karidefer-Szerszen M. The effect of heat shock, cisplatin, etoposid and quercetin on Hsp72 expression in human normal and tumor cells. Pol J Pathol. 2002, 53, 133-137.
13. Hu W, Kavanagh J. Anticancer therapy targeting the apoptotic pathway. The Lancet Oncol. 2003, 4, 721-729.
14. Ding Z, Yang X, Pater A, Tang S. Resistance to apoptosis is correlated with the reduced caspase-3 activation and enhanced expression of antiapoptotic protein in human cervical multidrug-resistant cells. Biochem Biophys Res Commun. 2000, 270, 415-420.
15. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein function and expression by kaempferol and quercetin. J Chemother. 2005, 17, 86-95.
16. van Zanden J, van der Wounde H, Vaesen J, [et al.]. The effect of quercetin phase II metabolism on ist MRP1 and MRP2 inhibiting potential. Biochem Pharmacol. 2007, 74, 345-351.
17. Surowiak P, Materna V, Kaplenko I, [et al.]. Augmented expression of metallothionein and glutathion S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005, 447, 626-633.
18. Materna V, Stege A, Surowiak P, [et al.]. RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells. Biochem Biophys Res Commun. 2006, 348, 153-157.